𝔖 Bobbio Scriptorium
✦   LIBER   ✦

139 Pharmacodynamic endpoints in the clinical development of molecularly targeted agents

Book ID
119515618
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
64 KB
Volume
73
Category
Article
ISSN
0167-8140

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Development of sorafenib and other molec
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma
✍ Andrew X. Zhu πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 205 KB

## Abstract It is well appreciated that hepatocellular carcinoma (HCC) represents one of the most challenging malignancies of worldwide importance. In fact, HCC is the fifth most common cancer and the third most common cause of cancer‐related death globally. The incidence rates for HCC in the U.S.